PE20040091A1 - Formulaciones farmaceuticas de liberacion controlada - Google Patents
Formulaciones farmaceuticas de liberacion controladaInfo
- Publication number
- PE20040091A1 PE20040091A1 PE2003000670A PE2003000670A PE20040091A1 PE 20040091 A1 PE20040091 A1 PE 20040091A1 PE 2003000670 A PE2003000670 A PE 2003000670A PE 2003000670 A PE2003000670 A PE 2003000670A PE 20040091 A1 PE20040091 A1 PE 20040091A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- release
- pde4d
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
QUE COMPRENDE: A)UN NUCLEO, QUE COMPRENDE: a)UNA COMPOSICION MEDICAMENTOSA; Y, b)UNA COMPOSICION HIDROHINCHABLE, TAL COMO UN AGENTE DE HINCHAMIENTO POLIMERICO IONICO O NO IONICO, OCUPANDO CADA UNO (a) Y (b) REGIONES SEPARADAS DENTRO DEL MISMO; Y, 2)UNA CUBIERTA ALREDEDOR DE (A), PERMEABLE AL AGUA, INSOLUBLE EN AGUA Y QUE TIENE AL MENOS UN PORO DE LIBERACION. DONDE, (a) COMPRENDE UN INHIBIDOR DE FOSFODIESTERASA TIPO 4D (PDE4D), O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE DICHA FORMULACION PRESENTA AL MENOS UNA DE LAS SIGUIENTES CARACTERISTICAS: i)UN Tmax MAYOR A 1,5 h CUANDO SE DOSIFICA IN VIVO; ii)MENOS DE 80% DE UN INHIBIDOR PDE4D O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, SE LIBERA IN VIVO APROXIMADAMENTE EN 1,5 h; iii)MENOS DE 80% DE UN INHIBIDOR PDE4D O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, SE LIBERA IN VITRO APROXIMADAMENTE EN 1,5 h; iv)UN RETRASO EN EL TIEMPO DE LIBERACION IN VITRO PREVIO A LA INICIACION DE LA LIBERACION DEL INHIBIDOR PDE4D, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ENTRE 0,5 h A 4 h; v)UN RETRASO EN EL TIEMPO DE LIBERACION IN VIVO PREVIO A LA INICIACION DE LA LIBERACION DE DICHO INHIBIDOR O SU SAL, DE ENTRE 0,5 h A 4 h. SIENDO DICHO INHIBIDOR ACIDO(R)-2-[4-({[2-(BENZO[1,3]DIOXOL-5-ILOXI)-PIRIDINA-3-CARBONIL]-AMINO}-METIL)-3-FLUORO-FENOXIL]-PROPIONICO, SU SAL FARMACEUTICAMENTE ACEPTABLE; o 2-(4-FLUOROFENOXI)-N-[4-(1-HIDROXI-1-METIL-ETIL)-BENCIL]-NICOTINAMIDA, O SU SAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39380102P | 2002-07-03 | 2002-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040091A1 true PE20040091A1 (es) | 2004-02-17 |
Family
ID=30115647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000670A PE20040091A1 (es) | 2002-07-03 | 2003-07-02 | Formulaciones farmaceuticas de liberacion controlada |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040076668A1 (es) |
| EP (1) | EP1519711A1 (es) |
| JP (1) | JP2006502108A (es) |
| AR (1) | AR040378A1 (es) |
| AU (1) | AU2003244942A1 (es) |
| BR (1) | BR0312410A (es) |
| CA (1) | CA2490978A1 (es) |
| MX (1) | MXPA05000303A (es) |
| PA (1) | PA8576801A1 (es) |
| PE (1) | PE20040091A1 (es) |
| TW (1) | TW200404580A (es) |
| UY (1) | UY27880A1 (es) |
| WO (1) | WO2004004684A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050186276A1 (en) * | 2003-07-17 | 2005-08-25 | Pfizer Inc | Pharmaceutical formulations |
| US20100209489A1 (en) * | 2009-02-04 | 2010-08-19 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
| WO2011039686A1 (en) * | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
| RU2607595C2 (ru) | 2010-02-03 | 2017-01-10 | Фарма Ту Б Лтд. | Составы разагилина с пролонгированным высвобождением и их применение |
| WO2015119848A1 (en) * | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3190176A1 (en) | 2020-07-29 | 2022-02-03 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE58906173D1 (de) * | 1989-03-31 | 1993-12-16 | Walhalla Kalk Entwicklungs Und | Verfahren zur Abtrennung von Arsen aus Abwässern. |
| TR200001847T2 (tr) * | 1997-04-04 | 2002-06-21 | Pfizer Products Inc. | Nikotinamid Türevleri |
| CZ20022046A3 (cs) * | 1999-12-23 | 2002-11-13 | Pfizer Products Inc. | Hydrogelem hnaná dávková forma účinné sloľky |
-
2003
- 2003-06-25 US US10/608,817 patent/US20040076668A1/en not_active Abandoned
- 2003-06-26 WO PCT/IB2003/002877 patent/WO2004004684A1/en not_active Ceased
- 2003-06-26 CA CA002490978A patent/CA2490978A1/en not_active Abandoned
- 2003-06-26 EP EP03738416A patent/EP1519711A1/en not_active Withdrawn
- 2003-06-26 MX MXPA05000303A patent/MXPA05000303A/es not_active Application Discontinuation
- 2003-06-26 JP JP2004519090A patent/JP2006502108A/ja not_active Withdrawn
- 2003-06-26 AU AU2003244942A patent/AU2003244942A1/en not_active Abandoned
- 2003-06-26 BR BR0312410-0A patent/BR0312410A/pt not_active IP Right Cessation
- 2003-07-02 AR ARP030102402A patent/AR040378A1/es unknown
- 2003-07-02 PE PE2003000670A patent/PE20040091A1/es not_active Application Discontinuation
- 2003-07-02 TW TW092118095A patent/TW200404580A/zh unknown
- 2003-07-03 UY UY27880A patent/UY27880A1/es not_active Application Discontinuation
- 2003-07-03 PA PA20038576801A patent/PA8576801A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2490978A1 (en) | 2004-01-15 |
| JP2006502108A (ja) | 2006-01-19 |
| US20040076668A1 (en) | 2004-04-22 |
| WO2004004684A8 (en) | 2004-12-29 |
| PA8576801A1 (es) | 2005-02-04 |
| MXPA05000303A (es) | 2005-03-31 |
| TW200404580A (en) | 2004-04-01 |
| UY27880A1 (es) | 2004-02-27 |
| AU2003244942A1 (en) | 2004-01-23 |
| BR0312410A (pt) | 2005-04-26 |
| EP1519711A1 (en) | 2005-04-06 |
| WO2004004684A1 (en) | 2004-01-15 |
| AR040378A1 (es) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040091A1 (es) | Formulaciones farmaceuticas de liberacion controlada | |
| PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
| DK1246622T3 (da) | Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse | |
| ATE355065T1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
| ES2159591T3 (es) | Composicion de liberacion controlada. | |
| AR013117A1 (es) | Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral | |
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| AR053731A1 (es) | Aromatizacion de gomas de mascar que contienen farmacos | |
| AR026745A1 (es) | Composiciones de eplerenona nanoparticulada | |
| TR200100931T2 (tr) | Yeni sürekli salınımlı oral formülasyonlar | |
| CO6241105A2 (es) | "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea y un anticoagulante u otro agente antiplaquetario" | |
| JP2005532372A5 (es) | ||
| AR027391A1 (es) | Composiciones farmaceuticas de toxina botulinica | |
| TR200200561T2 (tr) | Mesalazin içeren ve vücut içinde kontrollü bir şekilde salgılanabilen ağızdan alınan farmasötik bileşimler | |
| JP2014512390A5 (es) | ||
| PE20030527A1 (es) | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen | |
| PE20080613A1 (es) | Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos | |
| IL158899A0 (en) | Pharmaceutical compositions for inhibiting angiogenesis containing oleuropein and derivatives thereof | |
| DK2170857T3 (da) | 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse | |
| WO2002026191A3 (en) | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue | |
| UY27588A1 (es) | Lactamas como antagonistas de taquiquininas | |
| EP1284265A4 (en) | BENZOTHIOPHENE DERIVATIVES AND MEDICINAL USE THEREOF | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| PE17897A1 (es) | Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano | |
| PE20051163A1 (es) | Formas de dosificacion oral de acido n-(2-(2-ftalimido-etoxi)-acetil)-l-alanil-d-glutamico (lk 423) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |